Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 8, 2000, Pages 2100-2108

  Korsinczky, Michael ^a,b   Chen, Nanhua ^a   Kotecka, Barbara ^a   Saul, Allan ^c   Rieckmann, Karl ^a   Cheng, Qin ^a  

^a AUSTRALIAN ARMY MALARIA INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4,6 DIAMINO 1,2 DIHYDRO 2,2 DIMETHYL 1 [3 (2,4,5 TRICHLOROPHENOXY)PROPOXY] 1,3,5 TRIAZINE; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; CYCLOGUANIL; CYTOCHROME B;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BINDING SITE; MALARIA FALCIPARUM; MOLECULAR MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMODIUM FALCIPARUM; POINT MUTATION; PRIORITY JOURNAL; RESPIRATORY CHAIN;

AMINO ACID SEQUENCE; ANIMALS; ANTIMALARIALS; ATOVAQUONE; BINDING SITES; CATTLE; CHICKENS; CONSERVED SEQUENCE; CYTOCHROME B GROUP; DRUG RESISTANCE; METHACRYLATES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; NAPHTHOQUINONES; PLASMODIUM FALCIPARUM; POLYENES; PROTOZOA; SEQUENCE HOMOLOGY, AMINO ACID; THIAZOLES;

EID: 0033931237     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.8.2100-2108.2000     Document Type: Article

References (34)

1. Cheng, Q., G. Lawrence, C. Reed, A. Stowers, L. Ranford-Cartwright, A. Creasey, and A. Saul. 1997. Measurement of Plasmodium falciparum growth rate in vivo: a test of malaria vaccines. Am. J. Trop. Med. Hyg. 57:495-500.
2. Chulay, J. D. 1998. Challenges in the development of antimalarial drugs with causal prophylactic activity. Trans. R. Soc. Trop. Med. Hyg. 92:577-579.
3. Crofts, A. R., and E. A. Berry. 1998. Structure and function of the cytochrome bc1 complex of mitochondria and photosynthetic bacteria. Curr. Opin. Struct. Biol. 8:501-509.
4. Davis, C. S., M. Pudney, P. J. Matthews, and R. E. Sinden. 1989. The causal prophylactic activity of the novel hydroxynaphthoquinone 566C80 against Plasmodium berghei infections in rats. Acta Leidensia 58:115-128.
5. Davis, C. S., M. Pudney, J. C. Nicholas, and R. E. Sinden. 1993. The novel hydroxynaphthoquinone 566C80 inhibits the development of liver stages of Plasmodium berghei cultured in vitro. Parasitology 106:1-6.
6. Desjardins, R. E., C. J. Canfield, D. Haynes, and J. D. Chulay. 1979. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdiluting technique. Antimicrob. Agents Chemother. 16:710-718.
7. Di Rago, J. P., J. Y. Coppee, and A. M. Colson. 1989. Molecular basis for resistance to myxothiazol, mucidin (strobilurin A), and stigmatellin. J. Biol. Chem. 264:14543-14548.
8. Fleck, S. L., M. Pudney, and R. E. Sinden. 1996. The effect of atovaquone (566C80) on the maturation and viability of Plasmodium falciparum gametocytes in vitro. Trans. R. Soc. Trop. Med. Hyg. 90:309-312.
9. Fowler, R. E., P. F. Billingsley, M. Pudney, and R. E. Sinden. 1994. Inhibitory action of the antimalarial compound atovaquone (566C80) against Plasmodium berghei ANKA in the mosquito, Anopheles stephensi. Parasitology 108:383-388.
10. Fry, M., and M. Pudney. 1992. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4″chlorophenyl)cyclohexyl]-3-hydroxy-1,4,-naphthoquinone (566c80). Biochem. Pharmacol. 40:914-919.
11. Fry, M., A. T. Hudson, A. W. Randall, and R. B. Williams. 1984. Potent and selective hydroxynaphthroquinone inhibitors of mitochondrial electron transport in Eimeria tenella (Apicocomplexa:Coccidia). Biochem. Pharmacol. 33:2115-2122.
12. Hutchinson, E. G., and J. M. Thornton. 1996. PROMOTIF-a program to identify and analyse structural motifs in proteins. Protein Sci. 5:212-220.
13. Iwata, S., J. W. Lee, K. Okada, J. K. Lee, M. Iwata, B. Rasmussen, T. A. Link, S. Ramaswamy, and B. K. Jap. 1998. Complete structure of the 11-subunit bovine mitochondrial cytochrome bc1 complex. Science 281:64-71.
14. Jones, G., P. Willett, R. C. Glen, A. R. Leach, and R. Taylor. 1997 Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267:727-748.
15. Limpaiboon, T., M. W. Shirley, D. J. Kemp, and A. Saul. 1991. 7H8/6, a multicopy DNA probe for distinguishing isolates of Plasmodium falciparum. Mol. Biochem. Parasitol. 47:197-206.
16. Looareesuwan, S., C. Viravan, H. K. Webster, D. E. Kyle, D. B. Hutchinson, and C. J. Canfield. 1996. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am. J. Trop. Med. Hyg. 54:62-66.
17. McIntosh, M. T., R. Srivastava, and A. B. Vaidya. 1998. Divergent evolutionary constraints on mitochondrial and nuclear genomes of malaria parasites. Mol. Biochem. Parasitol. 95:69-80.
18. Morris, A. L., M. W. MacArthur, E. G. Hutchinson, and J. M. Thornton. 1992. Stereochemical quality of protein structure coordinates. Proteins 12: 345-364.
19. Oduola, A. M., W. K. Milhous, N. F. Weatherly, J. H. Bowdre, and R. E. Desjardins. 1988. Plasmodium falciparum: induction of resistance to mefloquine in cloned strains by continuous drug exposure in vitro. Exp. Parasitol. 67:354-360.
20. Ranford-Cartwright, L. C., J. Taylor, T. Umasunthar, L. H. Taylor, H. A. Babiker, B. Lell, J. R. Schmidt-Ott, L. G. Lehman, D. Walliker, and P. G. Kremsner. 1997. Molecular analysis of recrudescent parasites in a Plasmodium falciparum drug efficacy trial in Gabon. Trans. R. Soc. Trop. Med. Hyg. 91:719-724.
21. Rathod, P. K., T. McErlean, and P. C. Lee. 1997. Variations in frequencies of drug resistance in Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 94:9389-9393.
22. Sabchareon, A., P. Attanath, P. Phanuaksook, P. Chanthavanich, Y. Poonpanich, D. Mookmanee, T. Chongsuphajaisiddhi, B. M. Sadler, Z. Hussein, C. J. Canfield, and D. B. A. Hutchison. 1998. Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 92:201-206.
23. Safwat, G., and P. K. Rathod. 1996. Frequency of drug resistance in Plasmodium falciparum: a nonsynergistic combination of 5-fluoroorotate and atovaquone suppresses in vitro resistance. Antimicrob. Agents Chemother. 40:914-919.
24. Srivastava. I., J. M. Morriaey, E. Darrouzet, F. Daldal, and A. B. Vaidya. 1999. Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites. Mol. Microbiol. 33:704-711.
25. Srivastava, I. K., H. Rottenberg, and A. B. Vaidya. 1997. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondria membrane potential in a malaria parasite. J. Biol. Chem. 272:3961-1966.
26. Sukwa, T. Y., M. Mulenga, N. Chisdaka, N. S. Roskell, and T. R. Scott. 1999. A randomized, double-blind, placebo-controlled field trial to determine the efficacy of Malarone™ (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. Am. J. Trop. Med. Hyg. 60:521-525.
27. Syafruddin, D., J. E. Siregar, and S. Marzuki. 1999. Mutations in the cytochrome b gene of Plasmodium berghei conferring resistance to atovaquone. Mol. Biochem. Parasitol. 104:185-194.
28. Thaitong, S., and G. H. Beale. 1981. Resistance of ten Thai isolates of Plasmodium falciparum to chloroquine and pyrimethamine by in vitro tests. Trans. R. Soc. Trop. Med. Hyg. 75:271-273.
29. Torres, R. A., W. Weinberg, J. Stansell, et al. 1997. Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Clin. Infect. Dis. 24:422-429.
30. Trager, W., and J. B. Jensen. 1976. Human malaria parasites in continuous culture. Science 193:673-675.
31. Vaidya, A. B., M. S. Lashgari, L. G. Pologe, and J. Morrisey. 1993. Structural features of Plasmodium falciparum cytochrome b that may underlie susceptibility to 8-aminoquinolines and hydroxynaphthoquinones. Mol. Biochem. Parasitol. 58:33-42.
32. Van Vugt, M., M. D. Edstein, S. Proux, K. Lay, M. Ooh, S. Looareesuman, N. J. White, and F. Nosten. 1999. Absence of an interaction between artesunate and atovaquone-proguanil. Eur. J. Clin. Pharmacol. 55:469-474.
33. Walker, D. J., A. E. Wakefield, M. N. Dohn, R. F. Miller, R. P. Baughman, P. A. Hossler, M. S. Bartlett, J. W. Smith, P. Kazanjian, and S. R. Meshnick. 1998. Sequence polymorphisms in the Pneumocystis carinii cytochrome b gene and their association with atovaquone prophylaxis failure. J. Infect. Dis. 178:1767-1775.
34. Zhang, Z., L. Huang, V. M. Shulmeisters, Y. I. Chi, K. K. Kim, L. W. Huang, A. R. Crofts, E. A. Berry, and S. H. Kim. 1998. Electron transfer by domain movement in cytochrome bc1. Nature 392:677-684.